Personalised Treatment Delivery – aHUS Agenda Topic 4
aHUS patients are likely to have personal preferences for a treatment and as more options become available a personalised approach for…
Meningococcal Infection – Symptoms
Complement Inhibitor users are the group at most risk of meningococcal infection according to the Centre for Disease Control in the…
Diagnosis – aHUS Agenda Topic 3
An accurate and rapid aHUS Diagnosis is essential to the best of aHUS patients health outcome. Our expert gave a response…
aHUS – Stopping eculizumab treatment safely
For aHUS patients stopping eculizumab (or even Ravulizumab) treatment is an important but emotive issue. Having had the treatment when seriously…
Closing the CaHUS knowledge gap
Two days ago an article appeared in BLOOD journal which was the result of a comprehensive analysis of data about patients…
Biosimilars – a Different type of aHUS Drug
Biosimilar drugs are having an increased presence in conversations about the aHUS therapeutic drug landscape. Here's why they're of interest.
USA
GLOBAL AHUS HIGHLIGHTS AND SCIENCE-BASED CONTENT
Are there 3000 aHUS patients in the USA
Health care and better estimating lead us to believe there are approaching 3000 aHUS patients in the USA who have survived…
aHUS and the foetus
There are two involved in a pregnancy and birth the mother and the foetus /baby. The mother may or may not…
aHUS meningococcal infection – vigilance essential
All aHUS patients know that when on complement inhibitor treatment they are at risk of meningococcal infection. Do they? Of course,…